vitalwiki

Fluocinolone Acetonide Topical Solution USP, 0.01%

RxNorm 1191310· FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01%· TOPICAL

Corticosteroid [EPC] · Encube Ethicals, Inc.

Indications and usage

INDICATIONS AND USAGE Fluocinolone acetonide topical solution USP, 0.01% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and administration

DOSAGE AND ADMINISTRATION Fluocinolone acetonide topical solution USP, 0.01% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Pregnancy

Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing mothers

Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Adverse events

Most frequently reported events (FDA FAERS). Report frequency does not imply causation.

  • inappropriate schedule of product administration2
  • application site erythema1
  • application site warmth1
  • hair colour changes1
  • incorrect dose administered1
  • intentional product misuse1
  • off label use1
  • product dose omission1
  • product quality issue1
  • product storage error1
  • scratch1
  • skin exfoliation1
  • skin hypertrophy1

Adverse reactions (label)

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Perioral dermatitis Itching Allergic contact dermatitis Irritation Maceration of the skin Dryness Secondary infection Folliculitis Skin atrophy Hypertrichosis Striae Acneiform eruptions Miliaria Hypopigmentation